Michalina A Montaño1,2, Maganizo B Chagomerana3,4, Margaret Borok5, Matthew Painschab4,6, Thomas S Uldrick7,8,9, Rachel A Bender Ignacio9,10,11. 1. Department of Biochemistry, University of Washington, Box 357236, Seattle, WA, 98195, USA. micham@uw.edu. 2. Department of Global Health, University of Washington, Seattle, WA, USA. micham@uw.edu. 3. UNC Project-Malawi, Tidziwe Centre, Private Bag A-104, Lilongwe, Malawi. 4. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 5. Department of Medicine, University of Zimbabwe College of Health Sciences, MP 167, Mount Pleasant, Harare, Zimbabwe. 6. Lineberger Comprehensive Cancer Center, 101 Manning Drive, 7305, Chapel Hill, NC, 27514, USA. 7. Global Oncology Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., D5-310, Seattle, WA, 98109, USA. 8. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 9. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 10. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA. 11. Harborview Medical Center, 325 9th Ave, 359929, Seattle, WA, 98104, USA.
Abstract
PURPOSE OF REVIEW: The relationship between antiretroviral therapy (ART) and cancer treatment outcomes among people living with HIV (PLWH) in low- and middle-income countries (LMICs) is complex and poorly understood for many cancers. We aimed to summarize existing evidence from LMICs regarding the benefit of ART on cancer treatment-related outcomes. RECENT FINDINGS: We included twelve observational studies that reported associations between ART status and cancer treatment outcomes among HIV-positive patients in LMICs. Most confirmed ART was associated with improved cancer treatment outcomes. Heterogeneity in cancers under study, outcome measurement, categorization of ART status, and reporting of HIV-related immune function made formal comparison between studies untenable. Where evaluated, ART generally has a positive effect on cancer outcomes in people with HIV in LMICs. However, there remains a substantial gap in the literature regarding the impact of ART on treatment outcomes for most cancer types. Future research should focus on the optimal timing and integration of ART and cancer treatment for PLWH with strategies applicable to constrained-resource settings.
PURPOSE OF REVIEW: The relationship between antiretroviral therapy (ART) and cancer treatment outcomes among people living with HIV (PLWH) in low- and middle-income countries (LMICs) is complex and poorly understood for many cancers. We aimed to summarize existing evidence from LMICs regarding the benefit of ART on cancer treatment-related outcomes. RECENT FINDINGS: We included twelve observational studies that reported associations between ART status and cancer treatment outcomes among HIV-positive patients in LMICs. Most confirmed ART was associated with improved cancer treatment outcomes. Heterogeneity in cancers under study, outcome measurement, categorization of ART status, and reporting of HIV-related immune function made formal comparison between studies untenable. Where evaluated, ART generally has a positive effect on cancer outcomes in people with HIV in LMICs. However, there remains a substantial gap in the literature regarding the impact of ART on treatment outcomes for most cancer types. Future research should focus on the optimal timing and integration of ART and cancer treatment for PLWH with strategies applicable to constrained-resource settings.
Authors: M Ceccarelli; E Venanzi Rullo; M A Marino; F d'Aleo; G F Pellicanò; F D'Andrea; A Marino; B Cacopardo; B M Celesia; G La Rocca; M Di Rosa; F Condorelli; M Berretta; G Nunnari Journal: Eur Rev Med Pharmacol Sci Date: 2020-04 Impact factor: 3.507
Authors: Gita Suneja; Meredith S Shiels; Rory Angulo; Glenn E Copeland; Lou Gonsalves; Anne M Hakenewerth; Kathryn E Macomber; Sharon K Melville; Eric A Engels Journal: J Clin Oncol Date: 2014-06-30 Impact factor: 44.544
Authors: Marcos Pedro Guedes Camandaroba; Raphael Leonardo Cunha de Araujo; Virgílio Souza E Silva; Celso Abdon Lopes de Mello; Rachel P Riechelmann Journal: J Gastrointest Oncol Date: 2019-02